Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

This study has been terminated.
(Safety concerns regarding the concomitant use of aliskiren with an ACEi or ARB.)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Pam Marcovitz, MD, William Beaumont Hospitals
ClinicalTrials.gov Identifier:
NCT00994253
First received: October 12, 2009
Last updated: July 30, 2012
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: October 2012
  Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)